Belzutifan for VHL syndrome: a real-world study
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital, Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests the drug belzutifan (a pill taken by mouth) in people with VHL syndrome who have kidney or other VHL-related tumors that are growing or can be measured. The study looks at how well belzutifan works in real-world conditions and whether certain genetic factors affect how the drug works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 14 years old or older.
- You must have a confirmed diagnosis of VHL syndrome (by genetic test or doctor's diagnosis).
- You must have at least one VHL-related tumor that can be measured on a scan or has grown recently.
- You must be able to take care of yourself (score 0–2 on the ECOG scale), meaning you can walk and do light work.
- You must not have had cancer unrelated to VHL in the last 3 years, except for certain skin cancers or cervical changes that were treated.
- You must not have a serious heart condition, bleeding disorder, active infection (like HIV, hepatitis B or C), or be on medications that affect the immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.
This study is for people who are already taking belzutifan in a related trial (LITESPARK-043) and want to continue treatment for advanced solid tumors or von Hippel-Lindau-related conditions. It tests the safety and effects of long-term use.
This trial tests a drug called belzutifan to see how it affects hormone levels in people with rare adrenal tumors (pheochromocytoma or paraganglioma). It may help control symptoms caused by excess hormones.
This trial tests a new drug called HS-10516 in people with VHL syndrome or advanced kidney cancer. The goal is to see if the drug can shrink tumors and what side effects it might have.
This trial studies whether propranolol, a beta-blocker medicine, can help people with VHL who have non-urgent hemangioblastomas in the brain/spinal cord. It aims to see if the medication is safe and beneficial without needing immediate surgery.
This trial studies the natural course and management of pancreatic neuroendocrine tumors in people with von Hippel–Lindau (VHL) disease. It may help doctors better predict how these pancreatic findings change over time and how to manage them.
Hear when a new Von Hippel-Lindau Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.